Dr. Wills is currently serving in board roles for GTx, Inc; Cymabay Therapeutics, Inc and Parion Sciences. Prior to that, Dr. Wills spent 25-years at Johnson & Johnson in a variety of senior roles in R&D and business development. Dr. Wills also worked ten-years in pharmaceutical drug development at Hoffmann-LaRoche.
"We are very pleased to have Rob join GO's Board of Directors," said Constantine Theodoropulos, Chief Executive Officer, GO Therapeutics. "As we chart GO's growth path, we will benefit greatly from Rob's ongoing board experience, extensive business development and R&D experience."
Dr. Wills added, "GO Therapeutics is an exciting company that has an opportunity to play an important role in the advancement of bispecific antibodies for T cell-redirection therapy, antibody-drug conjugates, and immune-based cell therapies. I look forward to transitioning to a board role and working closely with the GO Therapeutics team to help achieve their strategic vision for the company."
About GO Therapeutics
GO Therapeutics is applying the latest advances in glycobiology to create cancer drugs that are more potent and less toxic. GO Therapeutics' cancer specific antibodies against tumor-specific antigens can be used in a multimodal approach to killing cancer, such as antibody-drug-conjugates, bi-specific T-cell engagers and immune-based cell therapies. The company's scientific team includes some of the leading scientific researchers and applied biologists in glycoproteomics. GO Therapeutics is based in Cambridge, MA. For more information please visit www.gotherapeutics.com.
To read more People News articles, click here.